CJC-1295 + GHRP-2 10mg
Dual-action GH secretagogue blend pairing a sustained GHRH analog with a pulsatile ghrelin receptor agonist for experimental GH research.
Mechanism
Stimulates the pituitary somatotropic axis simultaneously via growth hormone-releasing hormone receptor signaling and ghrelin/GHS-R agonist pathways to elicit sustained yet pulsatile endogenous growth hormone secretion.
Dosing
Preclinical investigation protocols frequently document an initial starting level of 150 mcg of the total reconstituted blend administered once per day.
Reconstitution
Adding 3.0 mL of bacteriostatic water to the 10 mg lyophilized blend yields a working concentration of roughly 3.33 mg/mL (33.3 mcg per U-100 unit).
Storage
Store the unmixed powder protected from light at 2–8 °C or frozen at -20 °C, and maintain the reconstituted liquid refrigerated at 2–8 °C for use within 2 to 4 weeks.
Mix & measure CJC-1295 + GHRP-2 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 + GHRP-2 10mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 66.7
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 150 mcg (1× daily, evening) | 4.5 units (0.045 mL) |
| Weeks 3–12 | 300 mcg (1× daily, evening) | 9.0 units (0.09 mL) |
| Weeks 1–2 (Advanced Split) | 100 mcg (2× daily) | 3.0 units (0.03 mL) |
| Weeks 3–12 (Advanced Split) | 150 mcg (2× daily) | 4.5 units (0.045 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water using an appropriate sterile syringe.
- 2
Gently inject the diluent down the inner glass vial wall to minimize foam production.
- 3
Slowly roll or swirl the vial between your palms until the cake is fully dissolved without vigorous agitation.
- 4
Record the date and resulting concentration (~3.33 mg/mL) on the vial and refrigerate at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized CJC-1295 + GHRP-2 (10 mg total blend) for reconstitution.
Insulin Syringes (U-100)
Precision U-100 syringes used to accurately draw micro-volumes of the reconstituted blend.
Bacteriostatic Water
Sterile diluent (3.0 mL per vial) containing benzyl alcohol to preserve multi-dose integrity.
Alcohol Swabs
Used to sanitize the vial rubber septum and the chosen experimental injection site.
Why researchers study it
Growth hormone and downstream IGF-1 output amplification
Adipocyte lipid mobilization and fat metabolism pathways
Lean musculoskeletal recovery and tissue preservation signaling
Slow-wave sleep architecture and nocturnal somatotropic release
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
CJC-1295 combined with GHRP-2 represents an investigational formulation designed to exploit two complementary pathways within the somatotropic axis. CJC-1295 acts as an engineered growth hormone-releasing hormone analog designed to resist enzymatic degradation, thereby prolonging endogenous GH-releasing tone and sustaining elevated downstream insulin-like growth factor 1 concentrations. Concurrently, GHRP-2 functions as a synthetic agonist of the growth hormone secretagogue receptor, prompting prompt pulsatile secretion. By uniting these two secretagogues into a single research-grade mixture, laboratory models aim to analyze potential synergistic dynamics in neuroendocrine signaling. The co-administration seeks to replicate both the baseline elevation and rapid episodic peaks typical of natural growth hormone dynamics, providing a robust platform for investigating muscle preservation, metabolic changes, and tissue recovery in non-clinical environments. This blend is strictly synthesized for preclinical laboratory experiments and holds no regulatory approval for medical administration. Preclinical research notes that systemic responses depend heavily on precise timing and glycemic conditions, requiring strict methodological protocols to assess true physiological responses.
References
- 1.Teichman SL et al., J Clin Endocrinol Metab, 2006 — CJC-1295 stimulation of GH and IGF-I secretion in healthy adults
- 2.Mericq V et al., J Clin Endocrinol Metab, 1998 — GHRP treatment in GH-deficient children
- 3.Pihoker C et al., J Clin Endocrinol Metab, 1998 — Pharmacokinetics and pharmacodynamics of GHRP-2
- 4.Laferrere B et al., J Clin Endocrinol Metab, 2005 — Effects of GHRP-2 on food intake and appetite
- 5.Arvat E et al., Peptides, 1997 — Comparative hormonal responses of GHRP-2 and hexarelin
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allGHK (Copper-Free) 50mg
Uncomplexed human tripeptide Gly-His-Lys researched for extracellular matrix remodeling and copper chelation dynamics.
View ProtocolEloralintide 10mg
Investigational once-weekly selective amylin-1 receptor agonist studied for body weight reduction and appetite regulation in clinical models.
View ProtocolPancragen 20mg
Synthetic pancreatic tetrapeptide (KEDW) studied in preclinical models for pancreatic cell differentiation and glucose regulation.
View Protocol